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Cells translate extracellular signals to regulate processes such as differentiation,
metabolism and proliferation, via transmembranar receptors. G protein-coupled
receptors (GPCRs) belong to the largest family of transmembrane receptors, with over
800 members in the human species. Given the variety of key physiological functions
regulated by GPCRs, these are main targets of existing drugs. During normal aging,
alterations in the expression and activity of GPCRs have been observed. The central
nervous system (CNS) is particularly affected by these alterations, which results in
decreased brain functions, impaired neuroregeneration, and increased vulnerability to
neuropathologies, such as Alzheimer’s and Parkinson diseases. GPCRs signal via
heterotrimeric G proteins, such as Go, the most abundant heterotrimeric G protein in
CNS. We here review age-induced effects of GPCR signaling via the Gi/o subfamily at
the CNS. During the aging process, a reduction in protein density is observed for almost
half of the Gi/o-coupled GPCRs, particularly in age-vulnerable regions such as the frontal
cortex, hippocampus, substantia nigra and striatum. Gi/o levels also tend to decrease
with aging, particularly in regions such as the frontal cortex. Alterations in the expression
and activity of GPCRs and coupled G proteins result from altered proteostasis,
peroxidation of membranar lipids and age-associated neuronal degeneration and death,
and have impact on aging hallmarks and age-related neuropathologies. Further, due
to oligomerization of GPCRs at the membrane and their cooperative signaling, down-
regulation of a specific Gi/o-coupled GPCR may affect signaling and drug targeting
of other types/subtypes of GPCRs with which it dimerizes. Gi/o-coupled GPCRs
receptorsomes are thus the focus of more effective therapeutic drugs aiming to prevent
or revert the decline in brain functions and increased risk of neuropathologies at
advanced ages.
Keywords: G protein-coupled receptors GPCRs, Gi/o heterotrimeric G proteins, aging, receptor density and
binding potential, frontal cortex, hippocampus, basal ganglia
G PROTEIN COUPLED RECEPTORS (GPCRs)
G Protein Coupled Receptors (GPCRs) comprise the largest family of transmembrane receptors,
with over 800 members present in humans (Fredriksson et al., 2003; Hauser et al., 2017). GPCRs
share a common structure of seven transmembrane helical regions, an extracellular N-terminus
and an intracellular C-terminus (Alexander et al., 2017). Due to this structure, GPCRs are also
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called 7-Transmembrane receptors (7-TM receptors). While the
first description of a crystalline structure of a non-GPCR 7-TM
protein was of the bacteriorhodopsin (Grigorieff et al., 1996), the
first GPCR to have its structure determined was bovine retinal
rhodopsin (Palczewski et al., 2000). From the more than 800
human GPCRs, around half have sensory functions that mediate
olfaction (about 400), taste (33), light perception (10) and
pheromone signaling (5) (Mombaerts, 2004). Of the remaining
non-sensory GPCRs, which account for over 370, more than
90% are expressed in the brain, and mediate signaling from
multiple types type of ligands, regulating several physiological
processes throughout the human organism, mainly endocrine
and neurological processes (Heng et al., 2013; Rask-Andersen
et al., 2014; Munk et al., 2016; Alexander et al., 2017; Huang
et al., 2017) (Figure 1A). GPCRs represent the most common
target for therapeutic drugs (Hauser et al., 2017). In 2017,
Hauser and coworkers by manually curating the Center Watch’s
Drugs in Clinical Trials database and by cross referencing with
public sources, have identified 475 approved medicine drugs that
target GPCRs, which accounted for around 34% of all FDA-
approved drugs (Hauser et al., 2017; Sriram and Insel, 2018).
This agrees with reports that estimated a proportion ranging
from 20 to 50% for drugs that have GPCRs as a target, with
discrepancies probably resulting from the varying definitions of
“drug target” (Heng et al., 2013; Rask-Andersen et al., 2014;
Laschet et al., 2018). As new functions for GPCRs are being
discovered, especially for the still around 100 orphan GPCRs
for which no endogenous ligand or clearly defined function
are currently known, the number of drugs targeting GPCRs
is expected to increase (Kroeze et al., 2003; Tuteja, 2009;
Laschet et al., 2018).
The first categorization of GPCRs became known as the ‘A-
F classification system.’ Created by Kolakowski (1994), it divided
GPCRs in six classes/families that share some sequence homology
and some functional similarities (Kolakowski, 1994). A seventh
class/family (‘O’) was added later on (Tuteja, 2009):
• Family A (rhodopsin receptor family), which includes
receptors for odorants, is the largest family of GPCRs and
was first divided into three groups (1–3) according to the
type of ligand (e.g., small ligands, peptides, high molecular
weight hormones such as FSH/TSH/LH) and the GPCR
region where to the ligands bind. Currently it has at least
19 known divisions/subfamilies.
• Family B (secretin receptor family) has about 60 members
(currently divided in 3 subfamilies), presents a large
N-terminal ectodomain and, although lacking the family
A structural signature, they have morphological similarities
to group A3. Their ligands include low molecular weight
hormones such as GH-RH, but mainly polypeptide
hormones such as glucagon, calcitonin, and secretin.
• Family C (metabotropic glutamate receptor family) has
about 24 members that also have large ectodomains for
ligand binding. Besides the different mGluR types, the
family also comprises GABA-B receptors and putative
pheromone receptors coupled to the heterotrimeric G
Protein Go.
• Family D (fungus pheromone receptor family) is not found
in vertebrates, and contains pheromone receptors (VNs)
associated with the heterotrimeric G protein Gi.
• Family E (cAMP receptor family) is comprised by cAMP
receptors (cAR) and is also not found in vertebrates.
• Family F (frizzled/smoothened receptor family) includes
the “frizzled” and “smoothened” receptors involved in
embryonic development and in cell polarity and division.
• Family O: GPCRs that did not belong to any of the
aforementioned families were later on assigned to a new
family termed O (for ‘Other’) (Tuteja, 2009).
An alternative classification system, termed “GRAFS,” was
proposed by Fredriksson et al. (2003), and divides GPCRs into
5 classes/families according to their primary sequence homology:
Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin.
The main differences between this nomenclature system and
the A-F(O) one are the division of Family B into Secretin and
Adhesion families, the inclusion of several unique classified
receptor proteins, and the Taste 2 receptors. The Secretin family
has 15 members that have an extracellular hormone-binding
domain, bind peptide hormones and have conserved cysteine
residues that form a network of three cysteine bridges in their
N-termini (Grauschopf et al., 2000). The Adhesion family is the
second largest GPCR family in humans, with 33 members, and
has long and diverse N-termini (Bjarnadóttir et al., 2004) and a
GPCR proteolytic (GPS) domain that Secretin receptors do not
have (Fredriksson et al., 2003; Lagerström and Schiöth, 2008).
Nowadays, pharmacologists generally use the GRAFS
sequence similarity family-based classification, supplemented by
a ligand-based functional classification. GPCRs usually bind to
more than one ligand, but are commonly known according to the
main endogenous one, such as dopamine or serotonin, in a third
ligand-based classification. This last will be the classification used
throughout this review, which will be focused on GPCRs coupled
to heterotrimeric G proteins of the Gi/o subfamily (Figure 1B).
HETEROTRIMERIC G PROTEINS OF THE
Gi/o SUBFAMILY
G protein-coupled receptors are so called since they translate
the signal from extracellular ligands into intracellular responses
via transducers named ‘heterotrimeric G proteins’ (Resende and
Vieira, 2012). Heterotrimeric G proteins are termed as such
due to their three subunits: α, β, and γ, with the first being a
GTP-binding protein with GTPase activity, and the latter two
forming a single inseparable complex usually called the Gβγ
subunit. Heterotrimeric G proteins are divided into four families
according to the functional and structural homologies of their Gα
subunits, which are responsible for the Gαβγ tri-complex main
properties: Gi/o, Gs, Gq/11, and G12/13 (Gudermann et al., 1996;
Offermanns, 2003; Hollmann et al., 2005; Yudin and Rohacs,
2018). The Gs proteins act as stimulators of adenylyl cyclases
(AC), leading to increased levels of cAMP and activation of
downstream pathways, including PKA; the Gq/11 proteins act
as stimulators of phospholipase C, which in turns produces the
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FIGURE 1 | Relative abundance of Gi/o-coupled GPCRs. (A) GPCRs’ main functions. There are about 800 human GPCRs, and around half have sensory functions
that mediate olfaction, taste, light perception and pheromone signaling. Another big slice of the pie belongs to non-sensory GPCRs that mediate signaling from other
type of ligands, mainly from hormones and neurotransmitters (NTs). (B) Relative abundance of Gi/o-coupled GPCRs in 13 human tissues/regions was taken from the
Human Protein Atlas (in Supplementary Table S1), quantitatively transformed (value 1 was attributed to ‘low’, 2.5 for ‘medium’ and 3.5 for ‘high’ abundance), and
the relative % of tissue distribution calculated by taking the sum of all abundance values, in all the 13 tissues, as 100%.
intracellular messengers DAG and IP3, resulting in the activation
of PKC and calcium signaling; the G12/13 proteins act as activators
of the RhoA small GTP binding protein and of phospholipase D
to regulate cell shape and motility; in contrast, the Gi/o proteins
are generally described as inhibitory, with AC and potassium
channels as their main effectors (Nobles et al., 2005; Milligan and
Kostenis, 2006; Yudin and Rohacs, 2018).
The Gi/o family is composed of 8 genes. The three Gi
proteins, Gαi1, Gαi2, and Gαi3, inhibit some adenylyl cyclase
isoforms (with ‘i’ referring to its inhibitory effect), reducing
the ability of basal and Gs-stimulated AC to generate cAMP.
Other members of this family are Gt1, Gt2 (transducin) and
Ggust (gustducin), together with Gz and Go proteins. Gt1/2 and
Ggust are involved in visual and taste functions, respectively, and
activate cGMP-phosphodiesterase. Gz inhibits AC, stimulates K+
channels and interacts with several protein RGSs. Gz is also
phosphorylated by protein kinase C (PKC) and p21-activated
kinase 1 (PAK1). Finally, the Go protein (‘o’ standing for
‘other’) was discovered during Gi purification from bovine brain
(Sternweis and Robishaw, 1984). Go effect on AC is not clear:
while initial reports indicated that Go did not inhibit AC (Katada
et al., 1986; Jiang and Bajpayee, 2009), more recent studies point
to its ability to inhibit the AC 1 isoform, although not the
AC V or VI ones (Birnbaumer, 2007). The Go gene (GNAO)
transcript is alternatively spliced into Gα1 and Gα2 variants, and
some studies suggest that Go ability to modulate AC activity
is primarily due to its less studied Go2 isoform or via its βγ
subunit (Kobayashi et al., 1990; Jiang and Bajpayee, 2009). Go
also seems to have a significant role in modulating several other
signaling pathways, including the STAT3 and ERK pathways
(van Biesen et al., 1996; He et al., 2005; Bikkavilli et al., 2008;
Jiang and Bajpayee, 2009; Zhao et al., 2016). All of these Gi/o
family members, except for the Gz protein, are inactivated by
the pertussis toxin (Offermanns, 2003; Hollmann et al., 2005)
and all induce K+ channels opening, besides functioning via
other transduction mechanisms. Gi/o-coupled GPCRs stimulate
GIRK (G-protein activated Inwardly Rectifying K+) channels
through direct interactions between Gβγ and the channel, leading
to hyperpolarization and thus decreased neuronal excitability
(Whorton and MacKinnon, 2013; Yudin and Rohacs, 2018).
Importantly, although Go is the most abundant heterotrimeric
G protein in the central nervous system (CNS), constituting
about 1% of the total membrane protein in the brain (Jiang and
Bajpayee, 2009), very little is known about its functions, with this
being particularly true for the Gα2 isoform (Jiang et al., 2001;
Jiang and Bajpayee, 2009; Wang et al., 2011; Tang et al., 2012).
In the classical model of activation/deactivation of G proteins,
the Gα subunit is in an inactive state when bound to GDP,
forming a complex with the Gβγ subunit. When a ligand binds
to a GPCR [the most common Guanine Nucleotide Exchange
Factor (GEFs)], the receptor changes its conformation and binds
to a heterotrimeric G protein, causing a conformational change in
the α subunit of the G protein. This causes the exchange of GDP
for GTP in the Gα subunit and the separation of the α subunit
from the βγ ones (and from the GPCR). At this point, the G
protein is active and both subunits (Gα and Gβγ) can interact
with and modulate the activity of several effector proteins. The
G protein signaling is terminated due to the intrinsic GTPase
activity of Gα, which hydrolyzes its GTP to GDP, with consequent
re-association of Gα to Gβγ and inactivation of the G protein
(Offermanns, 2003; Hollmann et al., 2005; Baltoumas et al., 2013).
Negative regulators, like Regulators of G protein signaling (RGS),
can bind to an activated Gα subunit and accelerate its GTPase
activity, leading to a faster inactivation and reassembling of the
heterotrimeric G protein (De Vries et al., 2000; Hollinger and
Hepler, 2002; Lin et al., 2014) (Figure 2A).
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FIGURE 2 | GPCR and G-proteins activation models. (A) Classical GPCR/G protein activation model. When inactive, heterotrimeric G proteins exist as a complex
comprising the α subunit (bound to GDP) and the βγ subunit. (1a) The binding of a ligand (as a neurotransmitter) to a GPCR results in a conformational change that
allows (1b) the binding of the receptor to the G protein. (2) This in turn causes a second conformational change on the α-subunit that results in the exchange of its
GDP by GTP, and the separation of the α and βγ subunits. (3) At this point the G protein is active, and both the α and βγ subunits interact with downstream effectors
to modulate different signaling pathways. (4) The G protein activation is terminated by the hydrolysis of the GTP molecule into GDP, a reaction that can be
accelerated by the binding of Regulators of G-protein Signaling (RGS) to the α subunit. (5) The GTP hydrolysis results in the re-formation of the trimeric complex,
bringing the G protein back to its inactive state. (B) Pre-coupled model(s). New mechanisms of GPCRs’ activation have emerged from various studies, particularly on
Gi/o-coupled GPCRs. In these, inactive GPCRs monomers (left) or homo/hetero dimers (right) exist in an inactive G protein-binding state. In some cases, effector
proteins (as adenylyl cyclase, AC) can even be part of the inactive pre-coupled receptorsome complex (not shown). (1) When the GPCR is activated by a ligand (as
dopamine, serotonin, etc.) (2) its coupled G protein becomes active by exchanging GDP by GTP and either dissociates from the GPCR and its βγ subunit to initiate
the signaling response (left) or remain associated to the complex and activate downstream effector proteins at the membrane (right). (3) In either case, the GTPase
activity (accelerated, e.g., by binding to RGS proteins) terminates the activation cycle for that G protein, and the GPCR-inactive G protein complex reassembles/is
reinstalled. Note that, in both classical and pre-coupled models, when an active Gα subunit dissociates from the GPCR, another cytosolic inactive heterotrimeric G
protein can bind to the activated GPCR to get activated, in an amplification mechanism. GIRK, G-protein activated Inwardly Rectifying K+ channel; PLC,
phospholipase C; PDE 6, phosphodiesterase 6.
Alternatively, a pre-coupled model (Figure 2B) has gained
ground, particularly for Gi/o-coupled GPCRs, the focus of
this review. In this, inactive GPCRs in the rest state are
in a heterotrimeric G protein-binding state from which they
dissociate when activated. When this occurs, the G protein is also
activated, exchanges GDP by GTP in the Gα subunit, and initiates
the signaling response. This also allows for the active GPCR to
bind to another G protein, in a catalytic activation and signal
amplification cycle (Figure 2B). This GPCRs-G protein pre-
coupled model explains why GPCRs have high affinity binding
to agonist ligands in the absence of GTP, and why many Gi-
coupled GPCRs can be co-purified with bound inactive Gi
protein (Carpenter et al., 2016; Gurevich and Gurevich, 2017;
Nehmé et al., 2017).
Indeed, several evidence have emerged supporting other
activation models than the classical one, including observations
that (1) GPCRs can form either hetero- or homodimers and
create functional pre-coupled complexes with heterotrimeric
G proteins in the rest state (Han et al., 2009; Parker et al.,
2011; Ferre et al., 2014; Nishimura et al., 2017; Prieto, 2017;
Durdagi et al., 2018; Navarro et al., 2018; Tóth et al., 2018;
Calebiro and Koszegi, 2019); (2) the G proteins can exist in a
pre-coupled complex with the GPCR and an effector protein,
as AC; further, binding of agonists to GPCR might result in
the activation of the G protein without its dissociation from
the complex (Ferré, 2015; Navarro et al., 2018); (3) some Gα
subunits can interact and modulate downstream signaling even
when bound to GDP (Kamakura et al., 2013; Lin et al., 2014);
(4) newly identified modulators of G protein activity, called
GEMs (guanine exchange modulators), can activate and inhibit
different Gα subunits through the same motif (Gupta et al., 2016;
Ghosh et al., 2017).
BRAIN-ENRICHED GPCRs COUPLED
TO Gi/o
Many of the physiological roles of GPCRs are determined by the
heterotrimeric G proteins to which they couple (Park et al., 2012;
Masuho et al., 2015). The coupling between GPCRs and the Gi/o
family is of particular interest in the brain since Gi/o proteins
are generally inhibitory, decreasing neuronal excitability, and can
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be the target not only for, e.g., analgesics, antipruritics, but also
for several modulatory medications (Yudin and Rohacs, 2018).
Further, the oligomerization properties that are emerging for
some of these GPCRs, together with the high abundance of Go
in the CNS (Jiang and Bajpayee, 2009) and its less understood
functions and signaling mechanisms, all these made Gi/o-coupled
GPCRs the central topic of this review.
From all GPCRs, 21.9% couple exclusively to the Gi/o
subfamily, and other 5% can couple to proteins of the Gi/o and
of other G subfamilies. Almost all of these GPCRs belong to the
Glutamate and Rhodopsin families (Offermanns and Rosenthal,
2008), but some receptors of the F/Frizzled/smoothened family
also have been reported to couple to Gi/o. These include Gi-
coupled smoothened receptors signaling for Sonic Hedghog
(Polizio et al., 2011a,b; Carbe et al., 2014; Cheng et al., 2018;
Ho Wei et al., 2018) and Frizzled 6 Wnt receptor (Kilander
et al., 2014a,b; Arthofer et al., 2016). Noteworthy, all these
receptors may couple differentially among different Gi and Go
isoforms, and specifically prefer one specific isoform to the
other(s) (Jiang et al., 2001, 2002; Jiang and Bajpayee, 2009; Wang
et al., 2011; Tang et al., 2012), a topic that should be further
explored by researchers.
Data regarding the relative protein abundance of Gi/o-
coupled GPCRs in human tissues was obtained from ‘The
Human Protein Atlas’ database (v16.1.proteinatlas.org) (Uhlén
et al., 2015), and is presented in the Supplementary Table S1.
A short summary of this table’s information is here shown as
a relative abundances chart (Figure 1B). This chart reveals
that GPCRs coupled to Gi/o have a wide distribution pattern
throughout various human body tissues/regions, being present
in virtually all human tissues in relevant amounts. Nevertheless,
Figure 1B also indicates that Gi/o-coupled GPCRs are highly
abundant in the brain, hematopoietic and immune system, lung,
gastrointestinal tract, endocrine tissue and reproduction systems,
while being slightly less abundant in pancreas, adipose and other
soft tissues. Based on this graph we have further focused this
review on Gi/o-coupled GPCRs highly abundant in the brain
(with a ‘high’ relative abundance in Supplementary Table S1)
and/or with high brain specificity (present in no more than 4
tissues other than brain). These criteria retrieved the following
12 GPCRs: adrenoceptors, dopamine receptors, acetylcholine
receptors, serotonin receptors, purinoceptors, opioid receptors,
somatostatin receptors, angiotensin receptors, cannabinoid
receptors, leukotriene receptors, metabotropic GABA receptors,
and metabotropic glutamate receptors. Lysophospholipid
receptors are also highly abundant in brain but also in various
other body tissues, and were here excluded.
Gi/o-coupled GPCRs have several functions within the
nervous system, and a better understanding of the mechanisms
regulated by these receptors is essential for the search of new
therapeutic targets (Liu et al., 2018). The functions of Gi/o-
coupled GPCRs can be detected and studied at a molecular and
cellular level, such as neurite outgrowth, neurotransmitter release
and synaptic plasticity, which are then translated into complex
brain functions, such as memory, learning, and cognition.
Serotonin, dopamine, cannabinoid, and metabotropic glutamate
receptors are involved in mechanisms of short and long-term
memory, memory consolidation, and learning (Abush and
Akirav, 2009; Leung and Wong, 2017). Opioid and serotonin
receptors are involved in the perception and processing of
pain (Dong et al., 2001; Diniz et al., 2015). Most GPCRs,
including dopamine, serotonin, and opioid receptors also play
a prominently role on modulating and influencing behavior
and emotions (Baik, 2013; Chu Sin Chung and Kieffer, 2013;
Nautiyal et al., 2015). Sleep and the regulation of the circadian
rhythm are also highly regulated by GPCRs signaling, although
it is not clear if the main GPCRs involved act through
the Gi/o family (Civelli, 2005, 2012; Tsuneki et al., 2016).
Additionally, GPCRs play a crucial role on brain development, by
modulating different mechanisms, such as neuronal migration,
neurite outgrowth and axonal elongation. Some of the GPCRs
responsible for these actions include somatostatin, dopamine,
and cannabinoid receptors (Leroux et al., 1995; Le Verche et al.,
2009; Ma’ayan et al., 2009; Zhang et al., 2009). A detailed list
of Gi/o-coupled GPCRs functions on the nervous system can be
found in Table 1.
AGE-INDUCED ALTERATIONS IN
BRAIN-ENRICHED Gi/o-
COUPLED GPCRs
Age-related alterations in neurotransmitters, their receptors, and
related neuromodulatory systems may affect the responsiveness
of receptors to neurotransmitters, leading to abnormal signal
transduction activity via the receptors themselves or via other
GPCRs they associate with at the membrane. As such, alterations
in GPCRs’ expression and activity with aging can be associated
to aging hallmarks and age-related pathologies. Decreased
expression or activity of GPCRs and G proteins have indeed
been associated to alterations in neuronal plasticity and increased
sensitivity to neurodegenerative processes, with a consequent
decline in cognitive, motor, and even sensory capabilities (Mesco
et al., 1991; González-Maeso et al., 2002; Mato and Pazos,
2004). These associations suggest a crucial role for GPCRs
in aging and in age-related and protein aggregation-associated
pathologies, such as Alzheimer’s, Parkinson’s, and Huntington’s
diseases, as well as vascular and frontotemporal dementia (Mesco
et al., 1991; González-Maeso et al., 2002; Alemany et al., 2007;
Huang et al., 2017).
Alterations in the signaling pathways evoked by GPCRs can
occur with age at various molecular levels, from ligand- or G
protein-GPCR interactions to downstream intracellular signaling
pathways involving the Gi/o effector proteins. Altered structure
or functionality of the plasma membranes’ lipids, and on the
membrane fluidity by lipid peroxidation, can all induce changes
in the GPCR’s activity and density (number of molecules in a
given region as a membranar nanodomain). In addition to the
lipid environment, the loss of receptors can result from reduced
protein synthesis and increased accumulation of aberrant non-
functional proteins due to impaired proteostasis (Gouveia et al.,
2017), and from cell degeneration and death due to trauma,
toxins or pathologies (Huguet et al., 1994; Cunha et al., 1995;
Alemany et al., 2007) (Figure 3).
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TABLE 1 | Brain-enriched and/or neurological-relevant GPCRs that can couple to the Gi/o subfamily, and their functions.
Receptor classes Gα protein GPCRs’ ligand(s) and general functions; subtypes and their specific functions
Adrenoceptors α2A
(ADRA2A)
Gi and Go Ligand: Adrenaline > noradrenaline
• Their activation causes platelet aggregation, blood vessel constriction and constriction of vascular smooth muscle;
• Presynaptically, these receptors inhibit the release of noradrenaline (negative feedback control);
• α2B and α2C: positive regulation of neuronal differentiation.
α2B
(ADRA2B)
α2C
(ADRA2C)
Dopamine
receptors
D2 (DRD2) Gi/Go Ligand: Dopamine
• Their activation mediates inhibitory dopaminergic neurotransmission;
• D2: important in the reward effects of morphine; knockout mice exhibit abnormal synaptic plasticity and display
reduced levels of aggression; adenohypophysis development; associative learning; axonogenesis; branching
morphogenesis of nerves; cerebral cortex GABAergic interneuron migration; chemical synaptic transmission,
postsynaptic; long-term memory; negative regulation of synaptic transmission, glutamatergic; neurological system
process involved in regulation of systemic arterial blood pressure; neuron-neuron synaptic transmission; orbitofrontal
cortex development; positive regulation of dopamine uptake involved in synaptic transmission; positive regulation of
glial cell-derived neurotrophic factor secretion; positive regulation of long-term synaptic potentiation; positive
regulation of neuroblast proliferation; prepulse inhibition; regulation of dopamine uptake involved in synaptic
transmission; regulation of long-term neuronal synaptic plasticity; regulation of synapse structural plasticity;
regulation of synaptic transmission, GABAergic; response to axon injury; striatum development; synapse assembly;
synaptic transmission, dopaminergic; visual learning.
• D3: their distribution is consistent with a role in cognition and emotional functions; implicated in modulation of
cocaine self-administration; promotes cell proliferation; learning or memory; negative regulation of oligodendrocyte
differentiation; prepulse inhibition; regulation of dopamine uptake involved in synaptic transmission; synaptic
transmission, dopaminergic; visual learning.
• D4: may be involved in the modulation of gastric acid secretion; responsible for neuronal signaling in the mesolimbic
system of the brain, an area of the brain that regulates emotion and complex behavior; modulates the circadian
rhythm of contrast sensitivity and inhibits adrenergic receptor-induced melatonin synthesis by α(1B)-D4 and β1−D4
receptors heterodimerization; knockout mice are supersensitive to several psychoactive substances, including
ethanol, cocaine, and methamphetamine; inhibitory postsynaptic potential; positive regulation of dopamine uptake
involved in synaptic transmission.
D3 (DRD3)
D4 (DRD4)
Acetylcholine
receptors
M2
(CHRM2)
Gi and Go Ligand: Acetylcholine
• Their activation mediates many of the effects of acetylcholine in the central and peripheral nervous system;
• Seem to function as autoreceptors;
• Knockout mice reveal an important neuromodulatory role for these receptors;
• M2: control of myocyte contraction; smaller role in the smooth muscle contractile response; may be involved in the
regulation of body temperature; nervous system development; synaptic transmission, cholinergic;
• M4: inhibitory autoreceptor for acetylcholine; activation of the receptor in the striatum inhibits dopamine-induced
locomotor stimulation in mice; synaptic transmission, cholinergic.
M4
(CHRM4)
Serotonin
receptors
5-HT1A
(HTR1A)
Gi/Go Ligand: Serotonin
• 5-HT1A: autoreceptors that inhibit cell firing; involved in many neuromodulative processes; implicated in the
neuroendocrine regulation of adrenocorticotropic hormone (ACTH); role in the regulation of 5-hydroxytryptamine
release, metabolism and levels in the brain – thereby affects neural activity, mood and behavior; plays a role in the
response to anxiogenic stimuli;
• 5-HT1B: induce presynaptic inhibition and influence behavior; vascular effects, such as pulmonary and cerebral
arteries vasoconstriction; may also have a role in the regulation of bone; regulates the release of
5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive
processing, pain perception, mood and behavior; chemical synaptic transmission; negative regulation of synaptic
transmission, GABAergic; negative regulation of synaptic transmission, glutamatergic;
• 5-HT1D: affect locomotion and anxiety; involved in vascular vasoconstriction in the brain; implicated in feeding
behavior, anxiety, depression; may have a stimulatory effect on growth hormone secretion; regulates the release of
5-hydroxytryptamine in the brain, and thereby affects neural activity; chemical synaptic transmission;
• 5-HT1E: exact function is presently unknown, due to the lack of selective ligands; may have an important
evolutionary role in humans and may be involved in the regulation of memory; chemical synaptic transmission;
• 5-HT1F: chemical synaptic transmission;
• 5-HT5A: may play a role in sleep and serve as a presynaptic serotonin autoreceptor; chemical synaptic transmission.
5-HT1B
(HTR1B)
5-HT1D
(HTR1D)
5-HT1E
(HTR1E)
5-HT1F
(HTR1F)
5-HT5A
(HTR5A)
Purinoceptors P2Y12
(P2RY12)
Gi/Go Ligand P2Y12 e P2Y13: ADP
Ligand P2Y14: UDP-glucose
• P2Y12: role in amplification of platelet activation and aggregation and blood coagulation; glial cell migration;
regulation of microglial cell migration;
• P2Y13: may play a role in hematopoiesis and the immune system.
P2Y13
(P2RY13)
P2Y14
(P2RY14)
(Continued)
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TABLE 1 | Continued
Receptor classes Gα protein GPCRs’ ligand(s) and general functions; subtypes and their specific functions
Opioid
receptors
δ (DOR-1) Gi and Go Ligand delta (δ): β-Endorphin, met/leu-enkephalin
Ligand kappa (κ): Dynorphin A
Ligand mu (µ): β-Endorphin > Dynorphin A > met/leu-enkephalin
Ligand OPRL1: Nociceptin/orphanin FQ
• δ: role in the perception of pain and in opiate-mediated analgesia; developing analgesic tolerance to morphine;
chemical synaptic transmission; neuropeptide signaling pathway;
• κ: are believed to mediate analgesia and sedation (perception of pain), miosis and dieresis; role in mediating reduced
physical activity and regulation of salivation upon treatment with synthetic opioids; may play a role in arousal and
regulation of autonomic and neuroendocrine functions; chemical synaptic transmission; neuropeptide signaling
pathway;
• µ: are believed to mediate analgesia, hypothermia, respiratory depression, miosis, bradycardia, nausea, euphoria,
and physical dependence; involved in neurogenesis; chemical synaptic transmission; neuropeptide signaling
pathway; positive regulation of neurogenesis;
• OPRL1: potential role in modulating various brain functions, including instinctive behaviors and emotions; role in
modulating nociception and the perception of pain; regulation of locomotor activity by the neuropeptide nociception;
chemical synaptic transmission; neuropeptide signaling pathway.
κ (KOR-1) Gi/Go
µ (MOR-1)
OPRL1
Somatostatin
receptors
SSTR1 Gi and Go Ligand SSTR1-4: somatostatin-14 = somatostatin-28.
Ligand SSTR5: somatostatin-28 > somatostatin-14.
• SSTR1: cerebellum development; forebrain development;
• SSTR2: growth hormone secretion; glucagon secretion; immune responses; mediates the inhibitory effect of
somatostatin-14; inhibits cell growth; stimulates neuronal migration; stimulates axon outgrowth; neuronal
development and maturation; mediates negative regulation of insulin receptor signaling through PTPN6; inactivates
SSTR3 receptor function; cerebellum development; forebrain development;
• SSTR3: inhibition of angiogenesis; cerebellum development; forebrain development; chemical synaptic transmission;
neuropeptide signaling pathway;
• SSTR4: arachidonate release; activation of mitogen-activated protein kinase cascade; anti-proliferative action in
tumor cells; cerebellum development; forebrain development;
• SSTR5: GH secretion; insulin secretion; increases cell growth; chemical synaptic transmission.
SSTR2
SSTR3
SSTR4
SSTR5
Angiotensin
receptors
AT1
(AGTR1)
Gi/Go,
Gq/11,
G12/13
Ligand: Angiotensin II > Angiotensin III
• Their activation mediates the cardiovascular effects of angiotensin II and angiotensin III (vasoconstriction, heart rate,
aldosterone secretion, blood pressure, and volume);
• Regulation of cell proliferation.
Cannabinoid
receptors
CB1
(CNR1)
Gi and Go Ligand: Anandamide and 2-arachidonoyl glyceride
• CB1: inhibition of ongoing release of excitatory and inhibitory neurotransmitters; axonal fasciculation; memory;
negative regulation of action potential; positive regulation of neuron projection development; regulation of synaptic
transmission, GABAergic and glutamatergic; trans-synaptic signaling by endocannabinoid, modulating synaptic
transmission; negative regulation of dopamine secretion;
• CB2: effect on the immunological activity of leukocytes; immune suppression; induction of apoptosis; induction of
cell migration; negative regulation of action potential; negative regulation of synaptic transmission, GABAergic.
CB2
(CNR2)
Leukotriene
receptors
LTB4R Gi/Go and
Gq/11
Ligand: Leukotriene B4
• LTB4R: may be the cardiac P2Y receptor involved in the regulation of cardiac muscle contraction; act as a
co-receptor; for macrophage-tropic Human immunodeficiency virus 1 (HIV-1) strains; causes chemotaxis;
neuropeptide signaling pathway;
• LTB4R2: mediates chemotaxis of granulocytes and macrophages; inhibit chemotaxis; neuropeptide signaling
pathway.
LTB4R2
Metabotropic
GABA
receptors
GABAB2
(GABBR2)
Gi and Go Ligand: γ-Aminobutyric acid (GABA)
• Involved in the fine tuning of inhibitory synaptic transmission; pre-synaptic GABA receptor is an inhibitory
neurotransmitter in the brain; postsynaptic GABA receptor decreases neuronal excitability; involved hippocampal
long-term potentiation, slow wave sleep, muscle relaxation and anti-nociception; gamma-aminobutyric acid signaling
pathway.
Metabotropic
glutamate
receptors
mGluR2
(GRM2)
Gi/Go Ligand: Glutamate
• mGluR2: may be involved in suppression of neurotransmission; may be involved in synaptogenesis or synaptic
stabilization; chemical synaptic transmission; glutamate secretion; regulation of synaptic transmission, glutamatergic;
• mGluR3: chemical synaptic transmission; regulation of synaptic transmission, glutamatergic;
• mGluR4: may have a role in modulation of glutamate transmission in the CNS; chemical synaptic transmission;
neurotransmitter secretion; regulation of neuronal apoptotic process; regulation of synaptic transmission,
glutamatergic;
mGluR3
(GRM3)
mGluR4
(GRM4)
(Continued)
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TABLE 1 | Continued
Receptor classes Gα protein GPCRs’ ligand(s) and general functions; subtypes and their specific functions
mGluR6
(GRM6)
• mGluR6: may have an important function in some inherited eye diseases; required for normal vision; chemical
synaptic transmission; regulation of synaptic transmission, glutamatergic;
• mGluR7: may have a role in modulation of glutamate transmission in the CNS; chemical synaptic transmission;
negative regulation of glutamate secretion; regulation of synaptic transmission, glutamatergic; sensory perception of
smell; sensory perception of sound; short-term memory; transmission of nerve impulse;
• mGluR8: presynaptic receptor may modulate glutamate release at the axon terminals of mitral/tufted cells in the
entorhinal cortex; regulation of synaptic transmission, glutamatergic.
mGluR7
(GRM7)
mGluR8
(GRM8)
Oxytocin
receptors∗
OT (OXTR) Gi/Go but
mainly
Gq/11
Ligand: Oxytocin
• Stimulates contraction of uterine smooth muscle and of mammary gland; stimulates milk secretion in response to
suckling; memory; positive regulation of synapse assembly, positive regulation of synaptic transmission, GABAergic
and glutamatergic; positive regulation of norepinephrine secretion; sleep; social behavior.
Adenosine
receptors∗
A1
(ADORA1)
Gi/Go Ligand: Adenosine
• A1: distributed widely in peripheral tissues where they have a mainly inhibitory role; cognition; excitatory postsynaptic
potential; negative regulation of long term synaptic depression; negative regulation of mucus secretion; negative
regulation of neurotrophin production; negative regulation of synaptic transmission, GABAergic; negative regulation
of synaptic transmission, glutamatergic; nervous system development; regulation of respiratory gaseous exchange
by neurological system process;
• A3: may play a role in reproduction.
∗The protein levels of these receptors in the brain were not reported in the Human Protein Atlas. However, as these GPCRs are known to play important functions in
the brain, and their protein levels decrease with age, they were also included in this analysis. Data was taken from UniProt (The UniProt Consortium, 2017) and InterPro
(Petryszak et al., 2016) database and included brain related Gene Ontology (GO) annotations (Molecular functions and Biological processes). ‘Gi and Go’, GPCRs that
couple with both Gi and Go proteins; ‘Gi/Go’, GPCRs known to couple with at least one of these Gα proteins (Gimpl and Fahrenholz, 2001; Guo et al., 2001; Hunyady
and Catt, 2006; Peres et al., 2007; Svízenská et al., 2008; Jiang and Bajpayee, 2009; McQuail et al., 2013).
A compilation of age-related alterations in the brain densities
of relevant Gi/o-coupled GPCRs and in their affinities to ligands
or other compounds, can be found in Supplementary Table S2.
Notwithstanding some contradictions, general lines could be
taken from the compiled studies and are discussed below.
A tendency can be observed for a general age-related decrease
in the brain density of these GPCR receptors. In fact, the
density of 64.3% of the studied Gi/o-coupled receptors subtypes
decreased with aging (corresponding to 44.1% of the density
studies). GPCRs densities were observed to increase in only
∼10.5% of the studies, although corresponding to the other
third of the analyzed GPCR subtypes (35.7%). Around 45.4% of
the studies retrieved unaltered GPCR densities with advanced
age. The affinity of the receptors to their ligands seems to not
have suffered as much with age as their density. Indeed, 78%
of the analyses to brain Gi/o-coupled GPCRs affinities did not
show alterations, ∼8.5% showed decreased affinity and 13.5%
increased affinity to ligands. When both parameters (density
and affinity) are combined in the ‘Binding potential’ of the
GPCRs to their ligands, an age-related decrease of 50.6% is
observed. Of note, the ‘Binding potential,’ which is calculated
as the ratio between Bmax (total density of the receptor) to KD
(the equilibrium dissociation constant of the tested radioligand),
is thus a parameter that decreases when the receptor’s density
decreases or when it has a higher tendency to dissociate from
its ligand, as for example a decrease binding to an agonist due
to a lower level of pre-coupled association with a G protein in
the resting state.
Age-associated changes vary not only between GPCRs
classes and subtypes, but also depending on the specific
brain region (Pascual et al., 1991; Bigham and Lidow, 1995;
Van Laere et al., 2008). These region-specific effects may be
ascribed to the different rates of neuronal differentiation and
maturation of the various brain regions (Sowell et al., 2003),
leading to different patterns and rates of receptors’ biosynthesis
and maturation after birth, besides the differential sensitivity to
external and internal hazard (Hamilton et al., 1984; Araki et al.,
1997). Specific information on age-related alterations of each
GPCR class and subtype is presented below.
Adrenoceptors
Age-associated changes in the densities of various adrenoceptors
vary with the subtype of receptor to the brain area and specific
layer (Bigham and Lidow, 1995). With age, the density of
adrenoceptors particularly decreases in the striatum and various
cortical regions (frontal, temporal, primary visual, prefrontal,
motor, and somatosensory cortices) (Nomura et al., 1986)
(Supplementary Table S2). The levels of α2-adrenoceptor may
decrease with age due to the known loss of presynaptic
noradrenergic terminals in layer I (Pascual et al., 1991;
Bigham and Lidow, 1995). This reduction can have important
functional consequences in synaptic integration of inputs
originated from different cerebral regions (Chu et al., 2003),
contributing to the motor and somatosensory deficits observed
in elderly individuals. Alterations in the brain adrenergic
system with advanced age seem to correlate with increased
depression and memory loss incidence (Arango et al., 1992;
Moore et al., 2005).
Abnormal CNS adrenergic activity has also been suggested in
patients with Alzheimer’s disease (AD), with a decrease in the
α2-adrenoceptor density being observed in AD patients’ brains
(Meana et al., 1992).
Frontiers in Aging Neuroscience | www.frontiersin.org 8 April 2019 | Volume 11 | Article 89
fnagi-11-00089 April 24, 2019 Time: 11:54 # 9
de Oliveira et al. Gi/o-Coupled GPCRS in the Aging Brain
FIGURE 3 | Main mechanisms of age-induced GPCRs decline. With aging, there is a general decrease in Gi/o-coupled GPCRs protein levels throughout the brain.
Though many elements are involved, there are three main factors: (1) alterations in the plasma membrane structure and fluidity caused by events like lipid
peroxidation; these lead to the instability of membrane proteins, including GPCRS, and result either in their altered function or decreased levels and densities at, e.g.,
signaling nanodomains; (2) hindered proteostasis: decreased protein synthesis due to alterations in transcription factors or increased mRNA instability, and
accumulation of aberrant GPCRs and other signaling proteins due to less efficient proteasome or autophagy (Aphg) quality control systems, may lead to a decrease
in the levels of functional GPCRs in the aged brain; (3) the increased incidence of neurodegenerative diseases and physical trauma with aging, together with
exposure to toxins, all lead to neuronal death. Moreover, the alterations in protein synthesis and membrane structure can eventually contribute to the onset or
progression of neurodegenerative pathologies, with a subsequent further decrease in some GPCRs’ levels.
Dopamine Receptors
The dopaminergic system modulates neurotransmission in areas
known for their vulnerability to aging, as the substantia nigra
and striatum (areas related to movement control and affected in
Parkinson’s disease, PD) and the hippocampus, a region with a
role in learning and memory (affected in AD) (Kaasinen et al.,
2000; Amenta et al., 2001).
Age-related decline in the dopaminergic neurotransmission
(including decreased protein and mRNA levels of the D2
receptors and their binding potential) has been observed in
various species, such as rabbits, rats and humans, and is one of the
more consistent manifestations of neural aging and age-related
degeneration (Thal et al., 1980; O’Boyle and Waddington, 1984;
Wong et al., 1984; Henry et al., 1986; Joyce et al., 1986; Lai et al.,
1987; Morgan et al., 1987; Seeman et al., 1987; De Keyser et al.,
1990; Mesco et al., 1991; Weiss et al., 1992; Antonini et al., 1993;
Rinne et al., 1993; Valerio et al., 1994; Wang et al., 1995; Ricci
et al., 1996; Kaasinen et al., 2000; Inoue et al., 2001; Villar-
Cheda et al., 2014; Matuskey et al., 2016; Dang et al., 2017)
(Supplementary Table S2). The decline of dopamine receptors
with aging might be a direct effect of the loss of dopaminergic
and their target neurons in the aging brain and/or the expression
of autoreceptors on dopamine neurons (Naoi and Maruyama,
1999; Branch et al., 2016; Dang et al., 2017). Indeed, cells in
the substantia nigra project to the striatum with a regionally
corresponding arrangement, and the observed reduction in
dopamine receptors may also result from cortical and thalamic
atrophy, and loss of striatal size with age (Morris et al., 1999;
Kaasinen et al., 2000; Raz et al., 2003). Further, the decline in
dopamine receptors also results from their reduced biosynthesis
and incorporation into the neuronal membranes, partially due
to decreased transcription in surviving dopaminergic neurons
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or increased receptor degradation (Morgan et al., 1987; Rinne,
1987; Han et al., 1989; Mesco et al., 1991; Antonini et al.,
1993; Valerio et al., 1994). As such, age-related decrease of D2
receptor in striatum and neuronal cell loss in the substantia
nigra have been associated to a decline in the synaptic dopamine
reuptake due to age-related decline of the dopamine transporter
(DAT) in the striatum (Ishibashi et al., 2009). Regarding gender,
Pohjalainen et al. (1998) reported gender-related differences in
D2 receptor affinity in the left striatum with age, which may
contribute to the differential vulnerability of men and women
to psychiatric disorders like schizophrenia (Pohjalainen et al.,
1998). In contrast to D2, the D3 receptor levels were shown to
increase with age in the striatum and nucleus accumbens, which
might represent increased D3 receptor function in these regions
to compensate D2 receptor striatal loss (Wallace and Booze,
1996). It is still controversial if D3 receptor levels change in the
aged human substantia nigra, since [11C]-(+)-PHNO binding to
D3 receptor was found either unaltered or increased (Nakajima
et al., 2015; Matuskey et al., 2016). Alterations in the D4 receptor
with age have been by far less studied (Valerio et al., 1994);
however, it would be interesting to understand if age-associated
circadian rhythm alterations are associated with altered D4
levels or their heterodimerization with adrenergic receptors
(α1B and β1), with consequent mis-regulation of adrenergic
receptor-induced melatonin synthesis (González et al., 2012).
As dopamine neurons are associated with motor, cognitive and
endocrine functions, the loss of dopamine neurons and receptors
with age most likely contributes to age-related decreased frontal
metabolism, cognitive and memory performances, and decreased
motor functions (Mesco et al., 1991; Valerio et al., 1994). Indeed,
the dopaminergic network seems to be intimately associated with
the senescence process. Most D2 dopamine receptors in the CNS
are coupled to the Go protein, with the usually robust ability of
GTP to regulate the binding affinity of dopamine to D2 receptors
being absent in Go-deficient mice (Jiang et al., 2001).
In agreement to its tight relation with aging, alterations
in dopamine receptors are also characteristic of age-related
pathologies as PD, but also of other disorders, such as Gilles de
La Tourette’s syndrome, depression, schizophrenia, and attention
deficit disorder (Meng et al., 1999; Rangel-Barajas et al., 2015;
Dang et al., 2017; Prieto, 2017).
Acetylcholine Receptors
Acetylcholine (ACh) receptors play an essential role in neural
network support, with their levels peaking very early (at 3 months
of age) in the rat hippocampus (Tice et al., 1996). Different
subtypes of ACh receptors appear to have different sensitivities
to aging, with mRNA and protein levels of the muscarinic M2
receptor suffering a more pronounced age-induced decrease than
the ones of the M4 receptors. Nevertheless, alterations in other
subtypes of muscarinic receptors may not be as relevant as for
M2. For example, significant changes in the density of the M1,
M3, and M4 receptor subtypes were detected in the cerebellum
but probably have a minimal impact on cerebellar function since
over 90% of the cerebellum muscarinic receptors belong to the
M2 subtype (Blake et al., 1991; Nordberg et al., 1992; Lee et al.,
1994; Tice et al., 1996) (Supplementary Table S2).
The age-related decrease in the M2 densities at the
hippocampus and frontal cortex may affect processes such
as learning and memory and other cognitive functions (Tice
et al., 1996; Scarr, 2012) (Table 1). Nieves-Martinez et al.
(2012) reported that normal, healthy aged rats have an age-
related increase in cognitive rigidity associated with reduced
muscarinic receptor function in the dorsomedial striatum,
even if there is no visible loss of M2/M4 receptor densities
(Nieves-Martinez et al., 2012).
Age-related loss of ACh receptors or impairment of their
function could also be implicated in the pathophysiology of age-
associated CNS diseases, such as Parkinson’s and Alzheimer’s
diseases (Tayebati et al., 2002, 2004; Piggott et al., 2003).
However, activation of M2 and M4 mAChRs receptors aggravated
the formation of the amyloid-β peptide and inhibited the
release of the neurotrophic sAPPα peptide, potentiating AD
(Thathiah and De Strooper, 2011).
Serotonin Receptors
Limbic and neuroendocrine control areas are under the influence
of serotonergic innervation (Arranz et al., 1993) and the effect of
aging on the serotonergic signaling has been thoroughly studied
(Supplementary Table S2).
Cognitive deficits (Arranz et al., 1993), changes in sleep
(Arranz et al., 1993; Meltzer et al., 2001), food intake (Arranz
et al., 1993; Meltzer et al., 2001), mood (Arranz et al., 1993),
circadian rhythms, neuroendocrine function, affective state,
memory and hormone secretion (Meltzer et al., 1998; Lerer
et al., 1999), and decreased libido (Arranz et al., 1993) are
some of the disturbances that have been attributed to age-
related changes in the serotonergic system (Matuskey et al., 2012).
Age-dependent decreases in 5-HT1-receptor binding potential
(mainly resulting from alterations in the 5-HT1A subtype,
see Supplementary Table S2) occur in the hypothalamus, in
various cortical regions including the frontal cortex, and in
the hippocampus and brainstem (these both only significantly
in men) (Meltzer et al., 2001; Tauscher et al., 2001; Parsey
et al., 2002; Matuskey et al., 2012). In the frontal cortex, there
is a decrease in the receptor’s affinity (Bigham and Lidow,
1995), as well as a decrease in G protein activation induced
by a 5-HT1A agonist (González-Maeso et al., 2002), revealing
this region as being highly affected by age. Contrarily, an
increase in 5-HT receptor binding potential was observed at
basal ganglia (putamen, pallidum) (Matuskey et al., 2012) and
enhanced downstream G protein signaling at the hippocampus
(Duncan and Hensler, 2002). Indeed, although the 5-HT1A
receptor density decreased in the aging hippocampal CA1
region (Burnet et al., 1994), 5-HT1A receptor-stimulated
[35S]GTPγS binding increased, representing a compensatory
mechanism at this region; this is not observed, e.g., in the
dentate gyrus, in spite of it also presenting decreased 5-
HT1A density (Duncan and Hensler, 2002). Gender-specific age-
related decreases in 5-HT1A binding potential (Supplementary
Table S2) were hypothesized to result from differences in
hormonal levels and distribution, as of circulating estrogen
(Meltzer et al., 2001). Reduction in 5-HT1 receptor density with
aging may result from decreased receptor synthesis (Palego et al.,
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1997), loss of neuronal cell bodies (Dillon et al., 1991) and/or
alterations in the lipid environment of neuronal cell membranes,
namely increase in viscosity and reduction in fluidity due to
lipid peroxidation (Dillon et al., 1991; Huguet et al., 1994;
Palego et al., 1997).
Pathological alterations of the 5-HT metabolism and/or loss
of serotonergic neurotransmission can also lead to several
CNS pathologies, including AD, schizophrenia, depression, and
anxiety. Serotonergic systems represent a potential therapeutic
target for the treatment of AD, since decreased serotonergic
neurons and/or reduction of serotonergic projections can be
observed in AD patients (Butzlaff and Ponimaskin, 2016).
Further, 5-HT1A receptor levels were reported to be decreased in
the hippocampus and frontal cortex of AD patients (Mizukami
et al., 2011; Verdurand and Zimmer, 2017). At a molecular level,
altered serotonin signaling seem to have a role in the production
of toxic amyloid proteins and amyloid plaques, leading to the
progression of the disease (Butzlaff and Ponimaskin, 2016).
Relatively to PD, a decrease in the 5-HT1A binding potential
has been detected in the midbrain raphe of PD patients,
correlating with the severity of tremors (Doder et al., 2003).
In parallel, the density of these receptors was observed to be
increased in the temporal cortex of patients with PD and Lewy
body dementia experiencing depression (Sharp et al., 2008;
Guerram et al., 2016).
Opioid Receptors
The opioid system is involved in the modulation of several
physiological processes, such as analgesia, stress response,
immune response, synaptic activation and neuroendocrine
function (Zhao et al., 2016). For example, kappa (κ) receptors
are located on presynaptic axonal terminals, modulating the
release of other classes of neurotransmitters, such as acetylcholine
and substance P (Svingos et al., 2001). Further, opioids induce
modifications in the endocrine system resulting in stimulatory
or inhibitory effects on hormone release (Vuong et al., 2010).
With advanced age, the capacity of opioids to regulate hormones
of the pituitary gland is decreased, and it is suggested that
receptor expression could depend on the endocrine environment
(Carretero et al., 2004).
Age-related decreased densities of opioid receptors have
been observed at the striatum, frontal poles, anterior cortex,
hippocampus (Hess et al., 1981; Piva et al., 1987; Maggi et al.,
1989) (Supplementary Table S2). The kappa receptors are the
main affected ones, being particularly decreased at the substantia
nigra, striatum (caudate and putamen) and various cortical
regions including the lateral agranular field of frontal cortex.
The potency of an antagonist of kappa receptors was also found
decreased in the medial pre-frontal cortex (Sirohi and Walker,
2015). The decreased opioid binding to kappa receptors may
result from age-related destruction of cell bodies and consequent
degeneration of axons (Hiller et al., 1992). On the other hand,
opioid signaling via the mu (µ) receptor seems to increase with
age at the prefrontal cortex, but its density is decreased at the
hypothalamus (González-Maeso et al., 2002).
The functions of the opioid system in learning and memory
(Thathiah and De Strooper, 2011; Zhao et al., 2016) support
a possible linkage between the opioid system and Alzheimer’s
disease (Mathieu-Kia et al., 2001), which is also reinforced by
the overlap between the distribution of opioid receptors and the
localization of the amyloid plaques in AD patients (Zhao et al.,
2016). Other links include the fact that opioids can modulate
the release of acetylcholine and substance P, already associated
with AD (Barg et al., 1993). Furthermore, the agonist-induced
activation of the human delta (δ) opioid receptor increases the
activities of β- and γ-secretase, which leads to the increased
production of the amyloid-β peptide (Sarajärvi et al., 2015).
Somatostatin Receptors
Somatostatin systems are highly expressed in the mammalian
brain and are involved in many brain functions such as motor
activity, sleep, and sensory and cognitive processes (Carretero
et al., 2004). Somatostatin receptors (SSTRs) are also involved in
some pathologies, such as Alzheimer’s disease, neuroendocrine
dysfunctions and several types of cancer (mainly the SSTR2
subtype in the case of human tumors) (Patel, 1999).
Down-regulation of somatostatin receptors was observed in
normal aging (Kumar, 2005; Gahete et al., 2010), and their
affinity to ligands decreases with age at hippocampus, striatum
and frontal cortex (Sirvio et al., 1987; Reed et al., 1999;
Shimokawa et al., 2000) (Supplementary Table S2). Importantly,
in contrast to rodents, human SSTRs maintain their density in
the cerebellum (Gonzalez et al., 1992; Laquerriere et al., 1994),
suggesting that somatostatin plays an important role in the
mature human cerebellum (Laquerriere et al., 1994).
A decline of somatostatin receptors (possibly SSTR2 and
SSTR4) was also observed in AD brains, and is related to the
degree of dementia (Kumar, 2005; Gahete et al., 2010). Indeed,
a decline in these receptors was observed to lead to reduced
action of neprilysin, an enzyme that degrades the amyloid-
β peptide, leading to the accumulation of amyloid-β in AD
senile plaques. As such, somatostatin receptors are potential
pharmacological targets for prevention and treatment of AD
(Burgos-Ramos et al., 2008).
Angiotensin Receptors
Angiotensin II, a ligand of angiotensin type 1 (AT1) receptors,
is known to be an inducer of inflammation and oxidative stress
(Villar-Cheda et al., 2012, 2014; Jackson et al., 2018).
Benigni et al. (2009) have observed that mice lacking
AT1 receptors have higher longevity due to their lower
oxidative stress, and have increased protection against age-related
progression of atherosclerosis (Benigni et al., 2009).
In fact, the inhibition of the AT1 receptor has been suggested
to aid in the attenuation of several cognitive pathologies
(Jackson et al., 2018). Increased activity of the local renin-
angiotensin system (RAS), via an increased expression of AT1
receptors in substantia nigra, seems to be involved in age-
related loss of dopaminergic neurons and in an increased risk
for PD due to the upregulation of NADPH-dependent oxidases
(Villar-Cheda et al., 2012, 2014; Jackson et al., 2018). Further,
inhibition of AT1 receptors in aged rats led to a decrease
in their higher susceptibility to dopaminergic neurotoxins
(Villar-Cheda et al., 2012, 2014).
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Cannabinoid Receptors
The cannabinoid system modulates multiple physiological
processes, mainly in the central motor system, being involved
in learning, memory, motor and reward processes, regulation
of pain mechanisms and protection against neuroinflammation
(Van Laere et al., 2008; Piyanova et al., 2013; Stumm et al., 2013).
Loss of cannabinoid 1 (CB1) receptors can result in
neuronal loss and cognitive deficits characteristic of the
aging brain (Piyanova et al., 2013; Stumm et al., 2013).
With advanced age, CB receptors decrease and undergo
biochemical and functional alterations in various cortical areas
and in extrapyramidal structures (Supplementary Table S2).
In the latter, selective degeneration of neurons with CB
receptors, and a reduction in receptor synthesis involving a
decline of mRNA levels, are possible mechanisms leading to
the visible CB receptor loss (Mailleux and Vanderhaeghen,
1992; Romero et al., 1998; Mato and Pazos, 2004). The
CB receptors also have their signaling through G proteins
decreased at substantia nigra and frontal cortex (Romero et al.,
1998; Mato and Pazos, 2004). These alterations are possibly
implicated in the pathophysiology of distinct neurological
and psychiatric disorders, such as PD, Huntington’s chorea,
AD, schizophrenia and depression (Romero et al., 1998;
Hurley et al., 2003; Mato and Pazos, 2004; Van Laere
et al., 2008; Wong et al., 2010; Takkinen et al., 2018),
with these receptors being considered a new target for drug
treatment of neuropsychiatric disorders. At a molecular level,
lack of CB1 receptors are suggested to influence the course
of brain aging via induction of lipofuscin accumulation,
reduced expression and activity of cathepsin D, and alterations
in lysosomal protease activity with subsequent decreased
degradation of damaged macromolecules in the hippocampus
(Piyanova et al., 2013). Regarding the binding potential, gender-
and region-dependent increases in the CB1 receptor binding
were detected in the human memory, limbic and motor
circuits (Van Laere et al., 2008). The authors hypothesize
that these alterations may reflect a way to compensate age-
related endocannabinoid dysfunction (decreased ligand levels at,
e.g., the hippocampus), functional losses in other monoamine
systems, or may even result from increased expression of
the receptors in non-neuronal elements such as glial cells.
Gender-dependent CB1R up-regulation can result, e.g., from
compensatory mechanisms modulated by sex hormones (Van
Laere et al., 2008). In mouse hippocampus (and parieto-temporal
cortex), an increase in [18F]FMPEP-D2 binding is observed
during aging, which could be a compensatory reaction against
to the age-related endocannabinoid dysfunction that has been
described in rodents (Maccarrone et al., 2001; Canas et al., 2009;
Takkinen et al., 2018).
The mRNA levels of CB1R were found to be significantly
decreased in the brains of patients with Parkinson’s disease,
specifically in the striatum (caudate nucleus and putamen)
and globus pallidus (Hurley et al., 2003). These alterations
not only indicate a connection between changes in the
dopaminergic system and the cannabinoid system, but also
reinforce the cannabinoid receptors as potential targets in the
treatment of PD.
Metabotropic GABA Receptors
GABA is the main inhibitory neurotransmitter, being involved
in a plethora of brain regulatory mechanisms (Petroff, 2002;
Ko et al., 2015).
As our brain gets older, the density of GABA receptors
particularly decreases in the frontal cortex (Supplementary
Table S2). Age-induced decreased GABAergic signaling can
have as consequence loss of memory and impaired cognitive
abilities, related to both medial temporal lobe and frontal
cortical systems (McQuail et al., 2012). These are brain regions
particularly vulnerable to aging alterations, and aged rodents
present frontal cortical dysfunction that causes loss of behavioral
flexibility (Barense et al., 2002; Schoenbaum et al., 2002; Rodefer
and Nguyen, 2008; McQuail et al., 2012). In humans, the
protein density of GABABR2 was found decreased in the
frontal cortex (McQuail et al., 2012), while unaltered in the
cerebellum, temporal gyrus, hippocampus, sensory and motor
cortices (McQuail et al., 2012; Pandya et al., 2019). In addition,
activation of the GABAergic signaling via downstream G proteins
is also decreased with age at the prefrontal cortex (González-
Maeso et al., 2002). Decreased GABAergic signaling may reflect
a decrease in the GABA receptors-containing nerve terminals
at specific brain regions, or be a consequence of peripheral loss
of input (Milbrandt et al., 1994; Caspary et al., 2008). It may
also relate to decreased function of its downstream Gi/o protein
signaling (discussed later on). A recent study reported an age-
related increase in the mRNA levels of several GABA receptors
in the primary visual cortex of rhesus monkeys, suggested to be
a compensatory feedback mechanism for the reduced release of
GABA found in this region (Liao et al., 2016).
In age-related Alzheimer’s pathology, GABAergic
neurotransmission undergoes a dynamic remodeling. Astrocytes
in AD brains were observed to have up-regulated GABA release,
which binds to extrasynaptic GABA receptors and inhibits
synaptic function, causing memory and cognitive deficits (Jo
et al., 2014). In this sense, GABA receptors may be promising
therapeutic targets for AD, using antagonists to alleviate
the inhibition of synaptic function and improve cognition
(Li et al., 2016).
Metabotropic Glutamate Receptors
Glutamate is considered the major excitatory neurotransmitter
in the mammalian brain (Hovelsø et al., 2012; Brosnan and
Brosnan, 2013), being implicated in diverse CNS signaling
pathways, mediating neuronal excitability, synaptic plasticity
and neurotransmitters’ release (Ferraguti and Shigemoto, 2006;
Brosnan and Brosnan, 2013; Zhou and Danbolt, 2014).
With aging there is an excessive glutamate release (Freeman
and Gibson, 1987), and increased glutamate-mediated
excitotoxicity has been widely reported in age-related diseases
(Sabelhaus et al., 2000). Regarding its receptors, there is an
age-dependent increase in protein and mRNA levels of group
II mGlu receptor proteins (mGluR2 and mGluR3). This occurs
in various brain regions (Angulo et al., 2003), including the
frontal cortex, striatum (caudate and putamen), thalamus,
cerebellum, and the hippocampus (Supplementary Table S2).
mGluR2/3 increased levels can result from increased synthesis
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of receptors to compensate the excessive release of glutamate
with aging (Simonyi et al., 2005). Contrarily, mGluR7 mRNA
levels decrease with age in various brain regions, and may
contribute to the age-related decline in sensory functions
(Simonyi et al., 2000).
Metabotropic glutamate receptors are extensively reported
to be involved in Alzheimer’s disease. For example, down-
regulation of group II mGluR signaling through the use of
antagonists may be a therapeutic approach for AD, since
these receptors stimulate the release of amyloid β42, the
predominant isoform of the amyloid-β peptide accumulated
in AD brains. However, group II mGluRs agonists have
shown to be neuroprotective against amyloid β toxicity
(Thathiah and De Strooper, 2011; Caraci et al., 2018).
Further, in the striatum and thalamus, agonists of group III
mGluR proteins (mGluR4, mGluR6, mGluR7, and mGluR8)
have an inhibitory effect on glutamate release, and may
counteract excitotoxic neurodegeneration associated with age-
related pathologies (Sabelhaus et al., 2000; Simonyi et al.,
2005). In this sense, activation of group III mGluRs has been
established to be neuroprotective (Ribeiro et al., 2017; Caraci
et al., 2018). Besides AD, these receptors are also implied in other
neurodegenerative diseases such as Parkinson’s and Huntington’s
diseases (Ribeiro et al., 2017).
The protein levels of the following two Gi/o-coupled GPCRs
are not available at the Human Protein Atlas database, but their
mRNA levels are quite abundant in brain. Further, they are
known to play important functions in the brain, and their protein
levels change with age. Hence, they were subsequently included
in this section.
Adenosine Receptors
Adenosine receptors are involved in the modulation of several
brain functions, such as cognition, neurodevelopment and the
sleep-awake cycle (Burnstock et al., 2011; Chen et al., 2014;
Huang et al., 2014).
With aging, a reduction in the turnover rate of adenosine
receptors (Fredholm et al., 1998) and a decline in the functional
output of the adenosine A1 receptor pathway (Meerlo et al.,
2004) have been observed. Reduction in the A1 receptor binding
may be related to a specific reduction in A1 receptor’s levels
(Pagonopoulou and Angelatou, 1992; Sperlágh et al., 1997; Meyer
et al., 2007), a specific neuronal loss, or alterations of the
neuronal set-up of A1 receptors, since there is a replacement
of neuronal cells by glial cells (Pagonopoulou and Angelatou,
1992; Cunha et al., 1995). It may also result from a modification
of the lipid environment of the receptor due to membrane
peroxidation, or by alterations in adenosine receptors’ mRNAs
due to a decreased transcription of the receptor gene and/or a
decrease in its mRNA stability (Cunha et al., 1995; Cheng et al.,
2000). These changes can have implications in the plasticity and
function of the brain, and be associated to ischemia/hypoxia,
dementia, and AD (Ekonomou et al., 2000; Meerlo et al., 2004;
Meyer et al., 2007).
Regarding the AD pathology, a significant increase in A1
receptors was observed in degenerating neurons presenting
neurofibrillary tangles, and in dystrophic neurites of senile
plaques in the hippocampus and frontal cortex of AD patients
(Angulo et al., 2003; Albasanz et al., 2008).
Oxytocin Receptors
Oxytocin (OT) receptors are present in the CNS, with
oxytocinergic neurons presenting widespread projections and
modulating synaptic transmission and network activity in the
hippocampus (Arsenijevic et al., 1995; Mairesse et al., 2015).
Age-related reduction in OT binding was reported in the
caudate putamen, the olfactory tubercle, and the ventromedial
hypothalamic nucleus of 20-month old rats. These reductions
were due to a decrease in the binding area rather than
from a decrease of the binding density within each area
(Arsenijevic et al., 1995). The authors also hypothesized a
link between this reduction in binding and a reduction in
steroid hormones, such as testosterone, detected in the aged
animals. This could be especially true for the olfactory tubercle
and the ventromedial hypothalamic nucleus, since previous
studies showed a modulatory effect of steroid hormones on
the expression of OT receptors in these areas (Tribollet et al.,
1990). Supporting this idea, a study showed that there were
no significant alterations in OT ligand binding in ‘steroid-
independent’ regions, such as the anterior olfactory nucleus, the
dorsal peduncular nucleus and the ventral subiculum. However,
this correlation between steroid action and OT binding did
not apply to all areas of the brain. In the bed nucleus of
stria terminalis and central amygdaloid nucleus, there were no
alterations in binding despite the sensitivity of these areas to
gonadal steroids. The loss of striatal OT receptors might also be
due to neuronal cell death, to a decrease in the striatal dopamine
content and of dopamine D2 receptors, since a stimulatory effect
on the secretion of OT has been suggested for dopamine in some
reproduction-related situations (Arsenijevic et al., 1995).
An analysis of the receptors discussed in this section indicates
that, during the aging process, there is mainly a reduction in
Gi/o-coupled GPCR densities in particular brain areas (further
summarized in Section “Conclusion”). This reduction most
probably results from peroxidation of the membrane, imbalanced
proteostasis (reduced biosynthetic capacity and impaired protein
quality control), and neuronal degeneration and death (Figure 3).
Additional insight on how these systems changes with age can be
gathered by taking into account the extent of the area affected
with aging and the differentially availability of the GPCRs in the
brain (Dang et al., 2017). Regarding receptors’ affinities, although
most of the studies reported no alterations, around 8.6% of
GPCRs showed decreased binding potential.
Besides alterations resulting from the normal aging of
the brain, altered GPCR signaling strongly correlates with
the development of age-associated and other neuropathologies
(Huang et al., 2017). In Alzheimer’s disease brains there
is a decline in the densities and/or function of, e.g., α2-
adrenoceptor (Meana et al., 1992), acetylcholine (Tayebati et al.,
2002, 2004), 5-HT1A serotonin (Mizukami et al., 2011; Butzlaff
and Ponimaskin, 2016; Verdurand and Zimmer, 2017), and
somatostatin receptors (Kumar, 2005; Gahete et al., 2010), but
an increase in adenosine A1 receptors (Albasanz et al., 2008).
Decreased serotonin, glutamate, somatostatin, adenosine, and
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opioid receptors/transmission have all been associated with
changes in cognitive and/or memory functions and with AD and
the degree of dementia, together with increased metabotropic
glutamate (group II mGluR) and extrasynaptic GABA signaling
(Mathieu-Kia et al., 2001; Kumar, 2005; Albasanz et al., 2008;
Gahete et al., 2010; Thathiah and De Strooper, 2011; Jo et al.,
2014; Sarajärvi et al., 2015; Butzlaff and Ponimaskin, 2016;
Li et al., 2016; Hauser et al., 2017; Caraci et al., 2018). In
Parkinson’s disease, the levels, binding potential and/or function
of GPCR receptors for dopamine (Meng et al., 1999; Rangel-
Barajas et al., 2015; Dang et al., 2017), acetylcholine (Tayebati
et al., 2002, 2004; Piggott et al., 2003) and serotonin (Doder
et al., 2003) were found decreased. Further, declines in the levels
of dopamine (Rangel-Barajas et al., 2015; Guerram et al., 2016),
serotonin (Doder et al., 2003; Sharp et al., 2008), acetylcholine
(Piggott et al., 2003; Tayebati et al., 2004), mGluR group III
glutamate (Ribeiro et al., 2017) and cannabinoid receptors
(Hurley et al., 2003) have been implicated in PD progression
and symptoms, as well as increased signaling via angiotensin
and mGluR group II metabotropic glutamate receptors (Villar-
Cheda et al., 2012, 2014; Ribeiro et al., 2017; Jackson et al., 2018).
Recent detailed information on the relation between GPCRs and
neuropathologies can be found in Guerram et al. (2016), Huang
et al. (2017), and Lütjens and Rocher (2017).
Degradation of specific Gi/o-coupled GPCR signaling with
aging and age-associated diseases may not only derive from the
decreased levels of that specific GPCR, but also of other molecular
players influencing the signaling mechanism, including the
main ligand, membranar lipids and other GPCR interactors
at the plasma membrane. These may include other GPCRs
with which the GPCR in question dimerizes/oligomerizes (see
below), regulators (e.g., GIT2, β-arrestin, allosteric regulators)
(Chen et al., 2001; Desai and Miller, 2018; Durdagi et al., 2018;
van Gastel et al., 2018), molecules of the signal transduction
machinery including the Gi/o transducers and the AC effector
(Kristiansen, 2004), all composing a functional receptorsome.
Recent studies show that many GPCRs (including dopamine
D1−3R, serotonin 5HT, angiotensin AT1R, purinoreceptor P2YR,
cannabinoid CB1, adrenergic β2AR, etc.) form functional homo-
and heterodimers to successfully translate extracellular signals
(Ferre et al., 2014; Nishimura et al., 2017; Prieto, 2017; Durdagi
et al., 2018; Tóth et al., 2018). Alterations in the assembly
of the GPCR receptorsome complexes can alter the affinity
to certain ligands, lead to desensitization or disruption of
the signaling mechanism, potentially explaining the decreased
binding potential and altered signaling detected in age-related
studies, including specific deregulations of GPCR signaling in
age-associated diseases (Grumolato et al., 2010; Ferré, 2015;
Prieto, 2017; Durdagi et al., 2018; Maroteaux et al., 2019).
These new mechanisms comprising GPCRs dimerization and
association with other signaling molecules reveal that GPCRs are
not single pharmacological entities and explain why alterations in
the plasma membrane, associated to aging and its diseases, affect
the efficacy of drugs targeting GPCRs (Desai and Miller, 2018).
Further, due to this oligomerization and cooperative character,
one may alter GPCR signaling by targeting other components of
the receptorsome (Nishimura et al., 2017; Durdagi et al., 2018),
including other GPCRs. For example, the targeting of the
AT1R angiotensin receptor, a signaling hub of receptor crosstalk
whose levels are increased in areas mainly affected by age,
is expected to aid in the recovery of signaling from other
GPCRs with which it dimerizes (Tóth et al., 2018). The new
knowledge on GPCR dynamics is thus a driving force in the
research and development of new therapeutic drugs for age-
associated diseases, from neurodegenerative to cardiovascular
diseases, osteoporosis, type 2 diabetes mellitus, etc. (Guerram
et al., 2016; Huang et al., 2017; Lütjens and Rocher, 2017;
Tóth et al., 2018; van Gastel et al., 2018; Calebiro and Koszegi,
2019; Maroteaux et al., 2019). To achieve this goal it is
necessary to understand how aging and age-associated disease
impact other receptorsome components such as the downstream
heterotrimeric G proteins.
Gi/o IN BRAIN DEVELOPMENT
AND AGING
With age, the signaling downstream several Gi/o-coupled GPCRs
is altered, and may also be ascribed to alterations in their
heterotrimeric G protein transducer. The alterations that these
proteins suffer during brain development and aging are presented
here, with a particular focus on Gαo, the most abundant Gα
subunit in the brain.
Regarding postnatal development, the brain mRNA levels of
Gαo and Gαi were found to be slightly higher at P1 than in
adulthood (Duman et al., 1989). Gαo and Gαi mRNA levels
increased during the first 7 days postnatally and then decreased
until P25 to levels equal to the adult brain. Gαs and Gβ (the other
Gα subunits analyzed) followed a similar pattern (Duman et al.,
1989). Of note, this study did not specify the age of adult rats, and
the characterization of a rat as “adult” or in ‘early adulthood’ can
be based in a large window of ages (P21 to P92) (McCutcheon
and Marinelli, 2009; Sengupta, 2013). There is some discrepancy
between these mRNA results and previous studies focusing on
the Gαo protein levels during this phase of development. In these,
Gαo protein levels were low at P1 and drastically increased during
the first weeks of development until around day 25, where they
achieved adult levels (Asano et al., 1988; Chang et al., 1988).
The differences could result from a lag in the processing of the
Gαo mRNA that affects the detection of the Gαo protein early
in development (Duman et al., 1989). On the other hand, they
could be due to alterations in the rate of Gαo protein turnover
during development, with Gαo exhibiting a higher turnover
rate at early stages of development, and a slower and more
stable turnover as the brain matures. This second hypothesis
was corroborated by follow up results demonstrating a slower
Gαo protein turnover with neuronal differentiation (Brabet et al.,
1991). Later studies also showed brain region-specificities of
Gαo levels. In rat cortex and thalamus, the protein levels of
Gαo1 (isoform 1 of Gαo) slightly rise on the first postnatal days
and then stabilize until adulthood (P90), while in the pituitary
gland and in hippocampus, Gαo1 levels significantly rise on the
first 10–20 days and then start to slowly decrease until P90
(Ihnatovych et al., 2002).
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The immunoreactivity of G proteins in the human brain has
also been assessed in post-mortem brains of human individuals
with ages ranging from 3 days to 92 years (Young et al., 1991). In
the whole brain, Gαi and Gαs (52 kDa form) immunoreactivities
were observed to significantly decrease with age. Gαo also
showed a tendency to decrease with age, although not statistically
significant. Gβ immunoreactivity presented no alterations with
age, while Gαs (45 kDa form) tended to increase. Specific
evaluation of Gαo in the pre-frontal cortex of human post-
mortem brains, however, revealed a more significant correlation
between aging and decreased Gαo immunoreactivity (Li et al.,
1996). Interestingly, neither Gαi nor Gαs exhibited major
alterations with aging in this brain area. Of note, the differences
between both studies can result not only from the different brain
region analyzed, but also from some interindividual variability
in the studied samples (Li et al., 1996). A later study showed a
decrease in both Gαo (slight) and Gαi (significant) levels in the
pre-frontal cortex with aging (González-Maeso et al., 2002), with
the differential results between studies potentially residing in the
range of ages represented in each study. While the Young et al.
(1991) and González-Maeso et al. (2002) studies used samples
from individuals with ages ranging from 3 days to 92-years-old
and 1 to 88-years-old, respectively, the Li et al. (1996) study used
samples from individuals with ages ranging from 19 to 100-years-
old (Young et al., 1991; Li et al., 1996; González-Maeso et al.,
2002). The lack of samples from younger individuals in the Li
et al. (1996) study and/or its older individuals might explain the
absence of alterations in Gαi levels, as well as the detection of a
significant decrease in Gαo levels.
The Li et al. (1996) study also compared control individuals
to individuals with Alzheimer’s Disease (AD), but no significant
differences were detected in G proteins levels besides a slight
decrease in Gαi1 (Li et al., 1996). These results are in accordance
with previous works that also showed no alterations in Gαo levels
in different regions of AD’s brains (McLaughlin et al., 1991;
O’Neill et al., 1994), with more recent studies also confirming
these results (Hashimoto et al., 2004). Despite the lack of
significant changes in Gαo levels in AD brains, Gαo signaling
was found deregulated in AD patients. Forms of amyloid
precursor protein (APP) with familial AD (FAD)-associated
V642 mutations, such as V642 to I (London FAD mutation), F
(Indiana FAD mutation) and to G (no FAD associated), have an
increased capability to activate Gαo, with this activation resulting
in apoptosis and associated DNA fragmentation (Okamoto et al.,
1995; Yamatsuji et al., 1996a,b). APP has also been shown to
induce cell death via a mechanism involving both Gαo and Src
activation (Sudo et al., 2000; Xu et al., 2009). There are also some
reports studying a possible link between Gαo and the Alzheimer’s
amyloid-β peptide (Aβ), with mixed results. While some reports
show that Aβ does not participate in the APP-Gαo induced
neuronal death (Sudo et al., 2001), others demonstrated that Aβ
toxicity in neuronal cells is dependent on APP binding to Gαo (via
deletion studies of the Gαo binding sequence) and Gαo activity
(via cells exposure to the Gαo inhibitor pertussis toxin, PTX)
(Shaked et al., 2009; Sola Vigo et al., 2009). These differences
might be due to the different experimental setups. The Xu study
intended to evaluate if Aβ mediated the neurotoxic effect of APP
upon its “activation” with specific antibodies, thus placing Aβ
downstream of APP Gαo interaction, while the Sola Vigo and
Shaked studies placed Aβ upstream the APP-Gαo interaction.
Gαo alterations have also been associated with other
neurological disorders. Although not age-related, these highlight
the role of Gαo in the brain. Briefly, the levels of Go in its
trimeric form are increased in Bipolar Affective Disorder brains
when compared to control individuals (Friedman and Wang,
1996); both Gαo mRNA and protein levels are decreased in the
prefrontal cortex of adult suicide victims, while in teenagers the
Gαo decrease is only detected in subjects with a history of mental
illness (Dwivedi et al., 2002).
Taking together, these studies indicate that Gαo expression in
the human brain changes during brain development and aging,
and that these alterations vary between different brain regions.
Moreover, while alterations in Gαo levels do not seem to be
associated with AD, a deregulation of Gαo signaling might play
an important role in this age-related disease.
CONSIDERATIONS ON AGE-RELATED
STUDIES ON GPCRs AND COUPLED G
PROTEINS
Although the studies here analyzed were generally consistent in
relation to an age-induced decreased in various GPCRs densities,
some studies reported no alterations or even an increase in the
same receptors’ densities. Differences between studies may be
related to the specific brain region studied (already addressed in
our approach to the GPCRs and G proteins studies), experimental
methodologies used, differences in species/strains/individuals,
age and gender/sex of the studied individuals.
Regarding the methodologies, several studies used ligands that
have different affinities for the receptors; further, these ligands
were sometimes non-selective or only slightly selective to the
subtype of GPCR (Arranz et al., 1993; Kaasinen et al., 2000;
Tayebati et al., 2001, 2002; Matuskey et al., 2016; Lebois et al.,
2018; Takkinen et al., 2018). Radioisotope ligand-binding assays
may also present some limitations. For example, the most used
isotope, 3H, emits β-particles of low energy that are differently
absorbed by tissues (Lidow et al., 1988). By its turn 125I emits high
energy particles that reduce the method’s resolution (Lidow et al.,
1988; Han et al., 1989). The receptors’ levels were also analyzed
by different techniques. The GPCRs’ mRNA was assessed by
Northern blot, or by the highly sensitive polymerase chain
reaction (qPCR) technique, useful when only small amounts
of tissue are available and when the target transcript is of low
abundance (Burnet et al., 1994). Importantly, mRNA levels not
always coincide with protein ones; as proteins are the GPCRs
functional molecules, we have here placed a main focus on
GPCRs’ protein levels (Simonyi et al., 2000; Yudin and Rohacs,
2018). Studies in postmortem tissues also have some restrictions
since delays and the freezing storage process (temperature and
tissue storage duration) may alter the integrity of receptors’
mRNA and protein (Mato and Pazos, 2004).
Additionally, changes in the aging brain may vary between
species, strains and even individuals (Rinne et al., 1990;
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Ekonomou et al., 2000; Yudin and Rohacs, 2018). Studies
have shown that humans and rhesus macaques have diverged
from mice due to a marked increase in age-dependent down-
regulation of neuronal genes’ expression (Loerch et al., 2008).
This is an evolved feature of the human (and macaque) aging
brain that might alter neural network and contribute to age-
related cognitive changes (Loerch et al., 2008). Despite common
neurodevelopmental processes in mammals, only a small subset
of age-related alterations in gene expression are conserved from
mouse to man (Loerch et al., 2008). In this way, experimental
animals cannot fully model human, with the evolutionary
distance between species being a limitation in scientific research
(Loerch et al., 2008; Silbereis et al., 2016). On the other hand,
morphological changes in the aging brain also depend on the age
of individuals (Ekonomou et al., 2000). Studies of the biology of
the aging brain using comparative survival curves for humans,
mice, and rhesus monkey, suggest that a 30-month-old mouse
is similar to an 81-year-old human and a 30-year-old rhesus
monkey is similar to a 70-year-old human (Loerch et al., 2008).
So, some contradictory reported results may be ascribed to
differences in the age of the animals used, and possibly some
age-related alterations might have been underestimated due to
such differences. Also, it is important to consider sample size,
as lower values will translate into low statistical power and can
cause discrepancies in studies. In techniques such as molecular
imaging, this is probably due to its high monetary cost and to the
desire to limit radiation exposure in healthy volunteers (Karrer
et al., 2017; Takkinen et al., 2018).
A clear comprehension on how gender/sex and age affect
(neuro)pathologies is very important, and these two factors
should be included as selection criteria or experimental
parameters in the design and interpretation of this type of studies
(Pandya et al., 2019). Regarding age, many studies have used only
‘under-aged’ subjects, such as rats and mice aged 24 months or
even less [e.g., the oldest mice used in Yew et al. (2009) study
were 12-months-old], or human individuals with ages ranging,
e.g., from 22 to 53 years old (Li et al., 1996; Tauscher et al.,
2001; Yew et al., 2009). In many studies, statistical significance
was only obtained in 30-month-old rats but not in 24-month-
old rats, which may justify contradictory results (Meyer et al.,
2007). Gender/sex can also influence the density and affinity of
GPCRs. Indeed, it appears to exist a gender/sex influence on
the control of the aging mechanisms, and in the structure and
function of the CNS, including in the synaptic alterations with
aging and age-related pathologies (Messing et al., 1981; Palego
et al., 1997). Some studies have addressed and revealed these
gender/sex-specific alterations in GPCRs levels and function in
animals and human samples (Supplementary Table S2).
It is thus important in the future to pay attention to these
variables, and increase the number of human studies covering
a good age interval and differentiating between both genders, in
order to minimize discrepancies in results and make it easier to
FIGURE 4 | Major alterations in Go/i-coupled GPCRs’ pathways in the aged brain, affecting four main areas. In the frontal lobe, particularly at the pre-frontal cortex
(1), the protein densities and/or affinity of α2 adrenoceptors, acetylcholine M2 receptors (M2), serotonin 5-HT1A receptors, opioid receptors (including the kappa
receptor, κ), somatostatin receptors (SSTRs), cannabinoid receptor CB1, the metabotropic GABAB receptor, and of the Gα proteins Gαo/i, are found decreased. The
same occurs in the (2) striatum, excluding the serotonin 5-HT1A receptors, the GABA metabotropic receptors and Gαo/i, and including dopamine D2 receptors and
the oxytocin (OT) receptors. The (3) hippocampus also presents decreases in the same receptors as the frontal cortex, with the exclusion of the adrenoceptors and
the GABAB receptor. Contrarily, mGluR2 and 3 glutamate receptors are up-regulated in these three brain areas. In the (4) substantia nigra, dopamine D2, opioid κ
and cannabinoid CB1 receptors are also depleted with age, while angiotensin AT1 receptor levels are increased.
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draw reliable conclusions on age-related GPCRs alterations in
the human brain.
CONCLUSION
This review shows that the main age-related hallmark of Gi/o-
coupled GPCRs is their decreased brain densities (and associated
binding potential), found in roughly two thirds of the subtypes of
receptors studied. This may result in loss of function, particularly
in brain regions where decreased density is associated with
altered binding/agonist association, and/or decreased G protein
levels or downstream signaling. Further, due to formation of
GPCR dimers at the membrane, the decreased density of a GPCR
may strongly affect the efficiency and the signaling pathway
of another GPCR (and the pharmacological treatment to be
applied). Some brain regions are more affected than others,
including (1) the cortex, particularly the frontal cortex but also
the temporal and other cortex lobes, (2) the striatum (caudate,
putamen, nucleus accumbens), (3) substantia nigra, and (4)
the hippocampus. These brain regions particularly sensitive
to aging are related to functions such as learning, planning
and execution, memory, and motor control. Homeostatic
functions, neuromodulation and neuroprotection via adenosine
and oxytocin receptors also decrease with age. On the other
hand, receptors related to inflammation, oxidative stress and
excitotoxicity have their densities increased with aging (Figure 4).
Since GPCRs are the largest family of transmembrane
receptors in humans and regulate several physiological functions,
and given that the heterotrimeric Gi/o family is the most
abundant in brain, these alterations significantly impair signal
transduction and lead to (or aid on) age-related senescence
processes and neuropathologies. With an increased aged
population, the Gi/o-coupled GPCRs signaling pathways are
thus to be seriously considered as targets to attempt to revert
the decline in cognitive and motor functions associated with
senescence, as well as increased sensitivity to neurodegeneration
at advanced ages.
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